FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:257-270 January 24, 2002 Number 4 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text CME Exam Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Migraine is a common, chronic, incapacitating neurovascular disorder, characterized by attacks of severe headache, autonomic nervous system dysfunction, and in some patients, an aura involving neurologic symptoms.^1,2 Recent advances in basic and applied clinical neuroscience³ have led to the development of a new class of selective serotonin (5-hydroxytryptamine [5-HT]) receptor agonists that activate 5-HT_1B and 5-HT_1D (5-HT_1B/1D) receptors and are known as the triptans; these agents have changed the lives of countless patients with migraine. Despite such progress, migraine remains underdiagnosed and the available therapies underused.⁴ In this article, we review the current understanding of the epidemiology, pathophysiology, and . . . [Full Text of this Article]

Clinical Manifestations

Pathophysiology

Migraine and the Brain

Pain Mechanisms

Drug Therapy

Preventive Therapy

Treatment of Acute Attacks

Analgesic and Nonsteroidal Antiinflammatory Drugs

Ergot Derivatives

The Triptans

            Pharmacology and Mechanisms of Action

            Safety and Tolerability

Meta-Analysis of Studies of Oral Triptan Therapy

Improvement at Two Hours

Sustained Freedom from Pain

Intrapatient Consistency of Response

Tolerability

Direct Comparisons

Parenteral Sumatriptan

Selecting Initial Treatment for Acute Attacks

The Future of Migraine Treatment

Source Information

From the Institute of Neurology, National Hospital for Neurology and Neurosurgery, London (P.J.G.); the Departments of Neurology, Epidemiology, and Social Medicine, Albert Einstein College of Medicine and the Montefiore Headache Unit, New York (R.B.L.); Innovative Medical Research, Towson, Md. (R.B.L.); and the Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands (M.D.F.).

Address reprint requests to Professor Goadsby at the Institute of Neurology, Queen Sq., London WC1N 3BG, United Kingdom, or at peterg@ion.ucl.ac.uk.

References

Related Letters:

Treatment of Migraine
Werner A., Wyderski R. J., Samuels N., Barker J. N., Ewart R. M., Klein A. W., Goadsby P. J., Lipton R. B., Ferrari M. D.
Extract | Full Text | PDF  
N Engl J Med 2002; 347:764-766, Sep 5, 2002. Correspondence

This article has been cited by other articles:

• Goadsby, P. J. (2008). Calcitonin gene-related peptide (CGRP) antagonists and migraine: Is this a new era?. Neurology 70: 1300-1301 [Full Text]  
• Ashkenazi, A, Matro, R, Shaw, J W, Abbas, M A, Silberstein, S D (2008). Greater occipital nerve block using local anaesthetics alone or with triamcinolone for transformed migraine: a randomised comparative study. J. Neurol. Neurosurg. Psychiatry 79: 415-417 [Abstract] [Full Text]  
• Park, K.-Y., Russo, A. F. (2008). Control of the Calcitonin Gene-related Peptide Enhancer by Upstream Stimulatory Factor in Trigeminal Ganglion Neurons. J. Biol. Chem. 283: 5441-5451 [Abstract] [Full Text]  
• Sakai, Y., Dobson, C., Diksic, M., Aube, M., Hamel, E. (2008). Sumatriptan normalizes the migraine attack-related increase in brain serotonin synthesis. Neurology 70: 431-439 [Abstract] [Full Text]  
• Salvatore, C. A., Hershey, J. C., Corcoran, H. A., Fay, J. F., Johnston, V. K., Moore, E. L., Mosser, S. D., Burgey, C. S., Paone, D. V., Shaw, A. W., Graham, S. L., Vacca, J. P., Williams, T. M., Koblan, K. S., Kane, S. A. (2008). Pharmacological Characterization of MK-0974 [N-[(3R,6S)-6-(2,3-Difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a Potent and Orally Active Calcitonin Gene-Related Peptide Receptor Antagonist for the Treatment of Migraine. J. Pharmacol. Exp. Ther. 324: 416-421 [Abstract] [Full Text]  
• Friedman, B. W., Greenwald, P., Bania, T. C., Esses, D., Hochberg, M., Solorzano, C., Corbo, J., Chu, J., Chew, E., Cheung, P., Fearon, S., Paternoster, J., Baccellieri, A., Clark, S., Bijur, P. E., Lipton, R. B., Gallagher, E. J. (2007). Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology 69: 2038-2044 [Abstract] [Full Text]  
• Goadsby, P. J (2007). MUMS the word. Migraine with unilateral motor symptoms: what can you say?. J. Neurol. Neurosurg. Psychiatry 78: 553-553 [Full Text]  
• Bigal, M. E., Lipton, R. B., Holland, P. R., Goadsby, P. J. (2007). Obesity, migraine, and chronic migraine: Possible mechanisms of interaction. Neurology 68: 1851-1861 [Abstract] [Full Text]  
• Rose, K. M., Wong, T. Y., Carson, A. P., Couper, D. J., Klein, R., Sharrett, A. R. (2007). Migraine and retinal microvascular abnormalities: The Atherosclerosis Risk in Communities Study. Neurology 68: 1694-1700 [Abstract] [Full Text]  
• Kurth, T., Gaziano, J. M., Cook, N. R., Bubes, V., Logroscino, G., Diener, H.-C., Buring, J. E. (2007). Migraine and Risk of Cardiovascular Disease in Men. Arch Intern Med 167: 795-801 [Abstract] [Full Text]  
• Brandes, J. L., Kudrow, D., Stark, S. R., O'Carroll, C. P., Adelman, J. U., O'Donnell, F. J., Alexander, W. J., Spruill, S. E., Barrett, P. S., Lener, S. E. (2007). Sumatriptan-Naproxen for Acute Treatment of Migraine: A Randomized Trial. JAMA 297: 1443-1454 [Abstract] [Full Text]  
• Zhang, Z., Winborn, C. S., Marquez de Prado, B., Russo, A. F. (2007). Sensitization of Calcitonin Gene-Related Peptide Receptors by Receptor Activity-Modifying Protein-1 in the Trigeminal Ganglion. J. Neurosci. 27: 2693-2703 [Abstract] [Full Text]  
• Akerman, S., Holland, P. R., Goadsby, P. J. (2007). Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular Neurons. J. Pharmacol. Exp. Ther. 320: 64-71 [Abstract] [Full Text]  
• Ahn, A. H., Basbaum, A. I. (2006). Tissue Injury Regulates Serotonin 1D Receptor Expression: Implications for the Control of Migraine and Inflammatory Pain.. J. Neurosci. 26: 8332-8338 [Abstract] [Full Text]  
• Kurth, T., Gaziano, J. M., Cook, N. R., Logroscino, G., Diener, H.-C., Buring, J. E. (2006). Migraine and risk of cardiovascular disease in women.. JAMA 296: 283-291 [Abstract] [Full Text]  
• Gupta, V. K. (2006). Orbitofrontal cortex hypometabolism, medication overuse headache, substance abuse and migraine: key pathophysiological issues.. Brain 129: E52-E52 [Full Text]  
• Kidd, D. (2006). The prevalence of headache in Behcet's syndrome. Rheumatology (Oxford) 45: 621-623 [Abstract] [Full Text]  
• Thijs, R. D., Kruit, M. C., van Buchem, M. A., Ferrari, M. D., Launer, L. J., van Dijk, J. G. (2006). Syncope in migraine: The population-based CAMERA study. Neurology 66: 1034-1037 [Abstract] [Full Text]  
• Hamel, E. (2006). Perivascular nerves and the regulation of cerebrovascular tone. J. Appl. Physiol. 100: 1059-1064 [Abstract] [Full Text]  
• Gordon, K E, Dooley, J M, Wood, E P (2006). Is migraine a risk factor for the development of concussion?. Br. J. Sports. Med. 40: 184-185 [Full Text]  
• Lipton, R. B., Bigal, M. E., Stewart, W. F. (2005). Clinical trials of acute treatments for migraine including multiple attack studies of pain, disability, and health-related quality of life. Neurology 65: S50-S58 [Abstract] [Full Text]  
• Holland, P. R., Akerman, S., Goadsby, P. J. (2005). Orexin 1 Receptor Activation Attenuates Neurogenic Dural Vasodilation in an Animal Model of Trigeminovascular Nociception. J. Pharmacol. Exp. Ther. 315: 1380-1385 [Abstract] [Full Text]  
• Nappi, R.E., Sances, G., Brundu, B., De taddei, S., Sommacal, A., Ghiotto, N., Polatti, F., Nappi, G. (2005). Estradiol supplementation modulates neuroendocrine response to M-chlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval. Hum Reprod 20: 3423-3428 [Abstract] [Full Text]  
• Goldszmidt, E., Kern, R., Chaput, A., Macarthur, A. (2005). The incidence and etiology of postpartum headaches: a prospective cohort study: [L'incidence et la cause des cephalees du postpartum : une etude prospective]. Canadian J. Anesthesia 52: 971-977 [Abstract] [Full Text]  
• Shindler, K. S., Sankar, P. S., Volpe, N. J., Piltz-Seymour, J. R. (2005). Intermittent headaches as the presenting sign of subacute angle-closure glaucoma. Neurology 65: 757-758 [Abstract] [Full Text]  
• Hatfield, L. A., Kossoff, E. H. (2005). Comorbidity of Epilepsy and Headache in Patients With Sturge-Weber Syndrome. J Child Neurol 20: 678-682 [Abstract]  
• Pietrobon, D. (2005). Migraine: New Molecular Mechanisms. Neuroscientist 11: 373-386 [Abstract]  
• Mortelmans, K., Post, M., Thijs, V., Herroelen, L., Budts, W. (2005). The influence of percutaneous atrial septal defect closure on the occurrence of migraine. Eur Heart J 26: 1533-1537 [Abstract] [Full Text]  
• Levy, M. J., Matharu, M. S., Meeran, K., Powell, M., Goadsby, P. J. (2005). The clinical characteristics of headache in patients with pituitary tumours. Brain 128: 1921-1930 [Abstract] [Full Text]  
• Akerman, S., Goadsby, P. J. (2005). The Role of Dopamine in a Model of Trigeminovascular Nociception. J. Pharmacol. Exp. Ther. 314: 162-169 [Abstract] [Full Text]  
• Barrett, C. F., Cao, Y.-Q., Tsien, R. W. (2005). Gating Deficiency in a Familial Hemiplegic Migraine Type 1 Mutant P/Q-type Calcium Channel. J. Biol. Chem. 280: 24064-24071 [Abstract] [Full Text]  
• Afridi, S. K., Matharu, M. S., Lee, L., Kaube, H., Friston, K. J., Frackowiak, R. S. J., Goadsby, P. J. (2005). A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain 128: 932-939 [Abstract] [Full Text]  
• Cao, Y.-Q., Tsien, R. W. (2005). Effects of familial hemiplegic migraine type 1 mutations on neuronal P/Q-type Ca2+ channel activity and inhibitory synaptic transmission. Proc. Natl. Acad. Sci. USA 102: 2590-2595 [Abstract] [Full Text]  
• Furman, J M, Balaban, C D, Jacob, R G, Marcus, D A (2005). Migraine-anxiety related dizziness (MARD): a new disorder?. J. Neurol. Neurosurg. Psychiatry 76: 1-8 [Full Text]  
• Shields, K. G., Goadsby, P. J. (2005). Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine?. Brain 128: 86-97 [Abstract] [Full Text]  
• Rose, K. M., Carson, A. P., Sanford, C. P., Stang, P. E., Brown, C. A., Folsom, A. R., Szklo, M. (2004). Migraine and other headaches: Associations with Rose angina and coronary heart disease. Neurology 63: 2233-2239 [Abstract] [Full Text]  
• Viney, T. J., Schmidt, T. W., Gierasch, W., Sattar, A. W., Yaggie, R. E., Kuburas, A., Quinn, J. P., Coulson, J. M., Russo, A. F. (2004). Regulation of the Cell-specific Calcitonin/Calcitonin Gene-related Peptide Enhancer by USF and the Foxa2 Forkhead Protein. J. Biol. Chem. 279: 49948-49955 [Abstract] [Full Text]  
• Goadsby, P. J (2004). To scan or not to scan in headache. BMJ 329: 469-470 [Full Text]  
• Gupta, V. K. (2004). Non-lateralizing brain PET changes in migraine: phenomenology versus pharmacology?. Brain 127: E12-E12 [Full Text]  
• McKendrick, A. M., Badcock, D. R. (2004). Decreased Visual Field Sensitivity Measured 1 Day, Then 1 Week, after Migraine. IOVS 45: 1061-1070 [Abstract] [Full Text]  
• Akerman, S., Kaube, H., Goadsby, P. J. (2004). Anandamide Is Able to Inhibit Trigeminal Neurons Using an in Vivo Model of Trigeminovascular-Mediated Nociception. J. Pharmacol. Exp. Ther. 309: 56-63 [Abstract] [Full Text]  
• Vickers, A. J, Rees, R. W, Zollman, C. E, McCarney, R., Smith, C. M, Ellis, N., Fisher, P., Van Haselen, R. (2004). Acupuncture for chronic headache in primary care: large, pragmatic, randomised trial. BMJ 328: 744- [Abstract] [Full Text]  
• Olesen, J., Diener, H.-C., Husstedt, I. W., Goadsby, P. J., Hall, D., Meier, U., Pollentier, S., Lesko, L. M., the BIBN 4096 BS Clinical Proof of Concept Study G, (2004). Calcitonin Gene-Related Peptide Receptor Antagonist BIBN 4096 BS for the Acute Treatment of Migraine. NEJM 350: 1104-1110 [Abstract] [Full Text]  
• Matharu, M. S., Bartsch, T., Ward, N., Frackowiak, R. S. J., Weiner, R., Goadsby, P. J. (2004). Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain 127: 220-230 [Abstract] [Full Text]  
• Potrebic, S., Ahn, A. H., Skinner, K., Fields, H. L., Basbaum, A. I. (2003). Peptidergic Nociceptors of Both Trigeminal and Dorsal Root Ganglia Express Serotonin 1D Receptors: Implications for the Selective Antimigraine Action of Triptans. J. Neurosci. 23: 10988-10997 [Abstract] [Full Text]  
• Marino, C. (2003). Acute Migraine Treatment Guideline. ANN INTERN MED 139: 603-603 [Full Text]  
• Letienne, R., Verscheure, Y., John, G. W. (2003). Investigation of the Effects of Naratriptan, Rizatriptan, and Sumatriptan on Jugular Venous Oxygen Saturation in Anesthetized Pigs: Implications for Their Mechanism of Acute Antimigraine Action. J. Pharmacol. Exp. Ther. 307: 168-174 [Abstract] [Full Text]  
• Ghafoor, V. L. (2003). Treatment of Chronic Pain. Journal of Pharmacy Practice 16: 249-260 [Abstract]  
• Bartsch, T., Goadsby, P. J. (2003). Increased responses in trigeminocervical nociceptive neurons to cervical input after stimulation of the dura mater. Brain 126: 1801-1813 [Abstract] [Full Text]  
• Evans, D. C., O'Connor, D., Lake, B. G., Evers, R., Allen, C., Hargreaves, R. (2003). ELETRIPTAN METABOLISM BY HUMAN HEPATIC CYP450 ENZYMES AND TRANSPORT BY HUMAN P-GLYCOPROTEIN. Drug Metab. Dispos. 31: 861-869 [Abstract] [Full Text]  
• Afridi, S, Goadsby, P J (2003). New onset migraine with a brain stem cavernous angioma. J. Neurol. Neurosurg. Psychiatry 74: 680-681 [Abstract] [Full Text]  
• Giffin, N.J., Ruggiero, L., Lipton, R.B., Silberstein, S.D., Tvedskov, J.F., Olesen, J., Altman, J., Goadsby, P.J., Macrae, A. (2003). Premonitory symptoms in migraine: An electronic diary study. Neurology 60: 935-940 [Abstract] [Full Text]  
• Khan, R. B. (2002). Migraine-Type Headaches in Children Receiving Chemotherapy and Ondansetron. J Child Neurol 17: 857-858 [Abstract]  
• Tottene, A., Fellin, T., Pagnutti, S., Luvisetto, S., Striessnig, J., Fletcher, C., Pietrobon, D. (2002). Familial hemiplegic migraine mutations increase Ca2+ influx through single human CaV2.1 channels and decrease maximal CaV2.1 current density in neurons. Proc. Natl. Acad. Sci. USA 99: 13284-13289 [Abstract] [Full Text]  
• Werner, A., Wyderski, R. J., Samuels, N., Barker, J. N., Ewart, R. M., Klein, A. W., Goadsby, P. J., Lipton, R. B., Ferrari, M. D. (2002). Treatment of Migraine. NEJM 347: 764-766 [Full Text]  
• Bartsch, T., Goadsby, P. J. (2002). Stimulation of the greater occipital nerve induces increased central excitability of dural afferent input. Brain 125: 1496-1509 [Abstract] [Full Text]  
• Matharu, M. S., Goadsby, P. J. (2002). Persistence of attacks of cluster headache after trigeminal nerve root section. Brain 125: 976-984 [Abstract] [Full Text]